As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
GLP-1 drugs like Novo Nordisk's Ozempic and Wegovy rank among the biggest medical breakthroughs in years, owing to their efficacy in treating obesity and type 2 diabetes, and reducing the risk of heart disease. Some 10 million Americans used them last year, a figure that could grow to 25 million by 2030, according to JPMorgan research.
We haven't written up this one. ETHealthworld has the full story — the link below goes straight to it.
